Floatz logo

Budesonide

Childhood Acute Lymphoblastic Leukemia

New York City Health and Hospitals CorporationSmall moleculePhase 4 / ApprovedDormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
81/ 100

Competitive context

65 Active assets in the Childhood Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
Vincristine sulfate
National Cancer Institute (NCI)
Phase 3BBB
Nivestim
St. Jude Children's Research Hospital
Phase 3BBB
METHOTREXATE
Children's Oncology Group
Phase 3BBB
Cytarabine
Children's Oncology Group
Phase 3BBB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 3BBB

View all 50 →

Same molecule, other indications

Budesonide is also rated in:

asthmaDormant
BBB
Indicative · Phase 4
79 / 100
View asset →
primary biliary cholangitisDormant
B
Indicative · Phase 3
60 / 100
View asset →
melanomaDormant
B
Indicative · Phase 2
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →